CBT profiles of cabozantinib approved for advanced renal cell carcinomas

Wang, Xiangdong

doi:10.1007/s10565-016-9349-6

Cited by 12 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was realized that drugs could change DNA repair mechanisms and cause the occurrence of gene mutations as an important part of toxicity three decades ago (Belitsky et al, 1985;Steinheider et al, 1986;Sinha et al, 1985). With the development of genetic technology, hereditary gene changes, mutations, and heterogeneity of human cells can result in the high susceptibility and resistance against drugs (Devine & Patani, 2017;Wang, 2016b;Wang, 2016c). Single-cell pooled CRISPR screening can play important role in understanding the mechanisms of genotoxicity and drug resistance.…”

mentioning

confidence: 99%

Single-cell CRISPR screening in drug resistance

Wang

2017

Cell Biol Toxicol

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

Single-cell CRISPR screening in drug resistance

Wang

2017

Cell Biol Toxicol

Self Cite

View full text Add to dashboard Cite

“…I am pleased to see editorials published in the journal in 2016 (e.g., Wang 2016;Mikó et al 2016). Wang (2016) describes the cell biology and toxicology profile of cabozantinib, which was recently approved by the FDA for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Mikó et al (2016) describe microbiome from a translational perspective.…”

mentioning

confidence: 99%

Understanding toxicology: mechanisms and applications

Bhatia

2016

Cell Biol Toxicol

View full text Add to dashboard Cite

How Far Can Mitochondrial DNA Drive the Disease?

Sun

Shi

Wang

2017

Mitochondrial DNA and Diseases

View full text Add to dashboard Cite

Mitochondria are one of the dominant drivers for producing cellular energy to meet a large number of biological functions, of which the mitochondrial DNA (mtDNA) is the control center of energetic driving force and the dominant driver of mitochondrial molecular diversification. mtDNA transcription generates the necessary RNAs to regulate the extent and nature of mtRNA post-transcriptional modifications and the activity of nucleus-encoded enzymes. With a special focus on mtDNA, the current volume aims to overview the biology and structures of mtDNA, regulatory roles of mtDNA in lung diseases, or involvement of mtDNA in metabolism. We explore the significance of mtDNA sequencing, methylation, stability, and mutation in the pathogenesis of the diseases. Molecular mechanisms by which mtDNA contribute to the regulation of mitochondrial homeostasis and drug resistance are also discussed. We also point out the importance of mitochondrial ribosome, single cell biology, and gene editing in the understanding of the development of mitochondrial dysfunction in lung disease.

show abstract

CBT profiles of cabozantinib approved for advanced renal cell carcinomas

Cited by 12 publications

References 15 publications

Single-cell CRISPR screening in drug resistance

Single-cell CRISPR screening in drug resistance

Understanding toxicology: mechanisms and applications

How Far Can Mitochondrial DNA Drive the Disease?

Contact Info

Product

Resources

About